These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36330532)

  • 61. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
    Tankova T; Senkus E; Beloyartseva M; Borštnar S; Catrinoiu D; Frolova M; Hegmane A; Janež A; Krnić M; Lengyel Z; Marcou Y; Mazilu L; Mrinakova B; Percik R; Petrakova K; Rubovszky G; Tokar M; Vrdoljak E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406370
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Catamenial diabetic ketoacidosis and catamenial hyperglycemia: case report and review of the literature.
    Ovalle F; Vaughan TB; Sohn JE; Gower B
    Am J Med Sci; 2008 Apr; 335(4):298-303. PubMed ID: 18414069
    [TBL] [Abstract][Full Text] [Related]  

  • 63. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
    Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Severe Diabetic Ketoacidosis in a Child with Type-1 Diabetes, Asthma, and COVID-19.
    Vasconez WA; Bustamante Escobar CL; Agarwal N; Solano JP; Sanchez JE
    J Pediatr Intensive Care; 2021 Sep; 10(3):232-234. PubMed ID: 34395043
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.
    Fralick M; Redelmeier DA; Patorno E; Franklin JM; Razak F; Gomes T; Schneeweiss S
    J Gen Intern Med; 2021 Sep; 36(9):2601-2607. PubMed ID: 33564942
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Population-based incidence of diabetic ketoacidosis in type 2 diabetes: medical claims data analysis in Japan.
    Takeuchi M; Kawamura T; Sato I; Kawakami K
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):123-126. PubMed ID: 28752620
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sodium Glucose Transporter 2 Inhibitors and Diabetic Ketoacidosis in Three Patients with Diabetes: Underlying Causation.
    Kelley JL; Strum M; Riche DM; Chandler AM
    J Pharmacol Pharmacother; 2017; 8(3):137-139. PubMed ID: 29081625
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors.
    Limenta M; Ho CSC; Poh JWW; Goh SY; Toh DSL
    Clin Drug Investig; 2019 Jul; 39(7):683-690. PubMed ID: 31065934
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
    Lee IH; Ahn DJ
    Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
    Jendle JH; Ampudia-Blasco FJ; Füchtenbusch M; Pozzilli P
    touchREV Endocrinol; 2021 Apr; 17(1):12-20. PubMed ID: 35118442
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
    Sahakian N; Cattieuw L; Ramillon-Cury C; Corroller AB; Silvestre-Aillaud P; Béliard S; Valéro R
    Clin Diabetes Endocrinol; 2021 Jul; 7(1):17. PubMed ID: 34281618
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Challenges in the Diagnosis of Euglycemic Diabetic Ketoacidosis in a Patient With Multiple Sclerosis Taking a Sodium-Glucose Cotransporter 2 Inhibitor.
    Allison R; Goldstein D; Musso MW
    J Emerg Med; 2019 Jul; 57(1):e1-e3. PubMed ID: 31027990
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hypertriglyceridemia with acute pancreatitis in a 14-year-old girl with diabetic ketoacidosis.
    Park H; Kim MS; Kim J; Lee SM; Cho SY; Yoo EG; Jin DK
    Ann Pediatr Endocrinol Metab; 2022 Mar; 27(1):73-77. PubMed ID: 34015902
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment outcomes of diabetic ketoacidosis among diabetes patients in Ethiopia. Hospital-based study.
    Mekonnen GA; Gelaye KA; Gebreyohannes EA; Abegaz TM
    PLoS One; 2022; 17(4):e0264626. PubMed ID: 35381004
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Successful management of severe diabetic ketoacidosis in a patient with type 2 diabetes with insulin allergy: a case report.
    Nguyen AD; Luong CQ; Chu HC; Nguyen VKD; Nguyen CV; Nguyen TA; Nguyen QH; Mai TD; Nguyen DV; Nguyen BQ; Tran TH; Dao PV; Nguyen DT; Nguyen NN; Do SN
    BMC Endocr Disord; 2019 Nov; 19(1):121. PubMed ID: 31711488
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Empagliflozin in type 1 diabetes.
    Mathieu C; Van Den Mooter L; Eeckhout B
    Diabetes Metab Syndr Obes; 2019; 12():1555-1561. PubMed ID: 31686876
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diabetic ketoacidosis: risk factors and management strategies.
    Umpierrez GE; Kitabchi AE
    Treat Endocrinol; 2003; 2(2):95-108. PubMed ID: 15871546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.